Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mackay Medical College manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions for this entity. This suggests a steady level of engagement with the patent office regarding biological and pharmaceutical research, reflecting the college's ongoing academic and commercial interests.
The prosecution involves 2 distinct examiners and 1 distinct art unit. While the college interacts with multiple examiners, all activity is housed within 1 distinct art unit. This structure indicates that while the technical focus is narrow, the college's applications are being reviewed by different individuals within that specific technical group. This can lead to different examination styles even within the same technological field, requiring a flexible legal strategy.
KEVIN E WEDDINGTON is the busiest examiner, with 1 busiest examiner pending office action. This represents 1 of the total 2 pending office actions for the portfolio. The other action is managed by the second of the 2 distinct examiners, showing an even distribution of the current workload across the examiners assigned to the college's filings. This balance ensures that the college's patent prospects are not entirely dependent on a single examiner's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| GIAMMONA, FRANCESCA FILIPPA | 1 | 37.5% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 14d |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843652 | METHOD FOR PREVENTING OR TREATING HEARING LOSS | WEDDINGTON, KEVIN E | — | §102 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18352651 | BIOCHIP AND METHOD FOR TRACKING POSTOPERATIVE RECURRENCE STATUS OF PATIENT WITH LUNG ADENOCARCINOMA | GIAMMONA, FRANCESCA FILIPPA | 1681 | §103§112 | Final Rejection | 14d | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial